Last reviewed · How we verify
NCT05859724
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
Phase 1 trial testing NM26-2198 in Atopic Dermatitis in 126 participants. Terminated before completion.
1 October 2024
Quick facts
| Lead sponsor | Yellow Jersey Therapeutics AG |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 126 |
| Start date | 10 May 2023 |
| Primary completion | 1 October 2024 |
| Estimated completion | 17 October 2024 |
| Sites | 15 locations across Canada, United States, Germany, Poland |
Drugs / interventions tested
- NM26-2198 — full drug profile →
- Placebo
Conditions studied
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
Sponsor
Yellow Jersey Therapeutics AG — full company profile →
Who can join
18 and older, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis.
Tietz J, Gunde T, Warmuth S, Weinert C, et al · · 2024 · cited 8× · PMID 38375189 · DOI 10.1016/j.xjidi.2024.100258 -
Emerging Systemic Treatment Options in Atopic Dermatitis.
Salman A, Giménez-Arnau AM. · · 2024 · cited 3× · PMID 38966900 · DOI 10.4274/balkanmedj.galenos.2024.2024-5-78
Verify or expand the search:
- PubMed search for NCT05859724
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
- NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05859724 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yellow Jersey Therapeutics AG
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05859724.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing